Back to News

DARPA Selects Continuity Pharma & Funds Continuous Manufacturing Technology Development

29 September 2020

The COVID-19 pandemic has created supply chain gaps in critical drug products, especially those needed for the most critical patients in intensive care units across the country.

DARPA (Defense Advanced Research Project Agency) has selected Continuity Pharma LLC to develop Continuous Manufacturing technology.  The company was selected for a $1.5 million grant.

DARPA has established a competitive review process, awarding grant funding to companies presenting Advanced Manufacturing Technologies.

Continuity Pharma’s mission is to apply novel Continuous Manufacturing capabilities to reshore generic drug products to the US, with specific focus on drugs in short supply.

“We are thrilled to be selected by DARPA to further our development efforts” said Prof. David Thompson, co-founder & Chief Scientific Officer. “We are one step closer to ensuring the availability of essential medicines to patients in need - it is an exciting time for Continuity Pharma.”

Grant specifics include development funding over the next 24 months, with additional funding for commercialisation in the subsequent 12 months.  Focus areas include capabilities for multiple API manufacturing in the Integrated Continuous Manufacturing System (ICMS), with demonstrated efficiencies for rapid changeover & manufacturing efficiencies.

About Continuity Pharma
Continuity Pharma was formed with the mission to ensure a consistent supply of high-quality essential medicines for patients in need.  We will accomplish this by applying analytical and process design expertise to create modular & portable Continuous Manufacturing systems for synthesising essential generic medicines.  Using high-throughput methodologies, we identify the ideal reaction conditions for preparing the active pharmaceutical ingredients (API) to be manufactured efficiently in continuous flow.  The result is a high yield of medical grade API with the least toxic waste & the best opportunity for production on scale.  For additional information or questions, please contact us at:

Other Recent Articles